Dudum Andrew's Form 4 filing
Hims & Hers Health, Inc. (HIMS) · filed Aug 7, 2024
- Accession no.
- 0001773751-24-000253
- Filed
- Aug 7, 2024
- Trade date
- Aug 5, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $5.50M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dudum AndrewCIK 0001837796 | Director, Officer (Chief Executive Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 5, 2024 | Class A Common Stock | MOption exerciseAcquired | +188,888 | $2.43 | +$458,997.84 | 222,390 | Direct | |
| Aug 5, 2024 | Class A Common Stock | SSaleDisposed | −100 | $16.87 | −$1,687 | 222,290 | Direct | |
| Aug 5, 2024 | Class A Common Stock | SSaleDisposed | −94,344 | $16.47F2 | −$1,553,845.68 | 127,946 | Direct | |
| Aug 5, 2024 | Class A Common Stock | SSaleDisposed | −94,444 | $16.47F3 | −$1,555,492.68 | 33,502 | Direct | |
| Aug 5, 2024 | Class A Common Stock | SSaleDisposed | −131,541 | $16.53F4 | −$2,174,372.73 | 889,993 | Indirect | |
| Aug 5, 2024 | Class A Common Stock | SSaleDisposed | −12,903 | $16.97F5 | −$218,963.91 | 939,934 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 5, 2024 | Class A Common Stock | MOption exerciseDisposed | −188,888 | $0.00 | $0 | 770,680 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $15.87 - $16.85. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $15.87 - $16.83. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $15.86 - $16.85. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $16.86 - $17.055. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.